The Glucagonoma Syndrome: A Review of its Features and Discussion of New Perspectives

Glucagonoma syndrome is a paraneoplastic phenomenon characterized by an islet alpha-cell pancreatic tumor, necrolytic migratory erythema, diabetes mellitus, weight loss, anemia, stomatitis, thromboembolism, and gastrointestinal and neuropsychiatric disturbances. These clinical findings in association with hyperglucagonemia and demonstrable pancreatic tumor establish the diagnosis. Glucagon itself is responsible for most of the observed signs and symptoms, and its induction of hypoaminoacidemia is thought to lead to necrolytic migratory erythema. Liver disease and fatty acid and zinc deficiency states may also contribute to the pathogenesis of the eruption in some cases. Most patients are diagnosed too late in the clinical course for cure, but successful palliation of symptomatology can usually be achieved with surgical and medical intervention. This paper reviews the glucagonoma syndrome, paying particular attention to its cutaneous features, and provides new perspectives in our current understanding of this phenomenon.

[1]  L. Elsborg,et al.  Effect of somatostatin in necrolytic migratory erythema of glucagonoma. , 2009, Acta medica Scandinavica.

[2]  M. Dohlsten,et al.  Immunological studies in a patient with the glucagonoma syndrome. , 2009, Acta medica Scandinavica.

[3]  M. Spellman Self-assessment examination of the American Academy of Dermatology. Skin papules and nodules. , 2003, Journal of the American Academy of Dermatology.

[4]  L. Gullo,et al.  Slow-release lanreotide treatment in endocrine gastrointestinal tumors , 1998, American Journal of Gastroenterology.

[5]  J. W. White,et al.  Apoptosis with positive direct immunofluorescence findings in a patient with necrolytic migratory erythema. , 1998, Cutis.

[6]  B. Balda,et al.  Erythema necrolyticum migrans nach Rektumadenokarzinom , 1998, Der Hautarzt.

[7]  Philip R. Cohen,et al.  Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. , 1998, Journal of the American Academy of Dermatology.

[8]  Stabile Be Islet cell tumors. , 1997, The Gastroenterologist.

[9]  M. McNeely,et al.  A Persistent Periorificial Eruption , 1997 .

[10]  J. Haefliger,et al.  In vivoin vitro effects of somatostatin and insulin on glucagon release in a human glucagonoma , 1997, Clinical endocrinology.

[11]  S. A. Sinclair,et al.  Necrolytic migratory erythema and zinc deficiency , 1997, The British journal of dermatology.

[12]  R. Schwartz,et al.  Glucagonoma and pseudoglucagonoma syndromes , 1997, International journal of dermatology.

[13]  S. Frankton,et al.  Gastrointestinal endocrine tumours. Glucagonomas. , 1996, Bailliere's Clinical Gastroenterology.

[14]  L. Kvols,et al.  Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. , 1996, Mayo Clinic proceedings.

[15]  J. Holst Glucagon, glucagon-like peptide-1 and their receptors: an introduction. , 1996, Acta physiologica Scandinavica.

[16]  C. Bunker,et al.  Successful treatment of a patient with octreotide–resistant necrolytic migratory erythema , 1996, The British journal of dermatology.

[17]  M. Ela.,et al.  Necrolytic migratory erythema without glucagonoma in patients with liver disease , 1996 .

[18]  A. Doolas,et al.  Rapid resolution of necrolytic migratory erythema after glucagonoma resection , 1996, Journal of surgical oncology.

[19]  L. Kvols,et al.  The glucagonoma syndrome. Clinical and pathologic features in 21 patients. , 1996, Medicine.

[20]  Philip R. Cohen,et al.  Cutaneous paraneoplastic syndromes in solid tumors. , 1995, The American journal of medicine.

[21]  J. W. White,et al.  45-year-old man with dermatitis and weight loss. , 1995, Mayo Clinic proceedings.

[22]  G. Manes,et al.  Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema? , 1995, The Italian journal of gastroenterology.

[23]  P. Lefèbvre Glucagon and its Family Revisited , 1995, Diabetes Care.

[24]  C. Baum,et al.  [Pseudoglucagonoma syndrome. Case report, therapeutic possibilities and hypotheses on the etiology]. , 1995, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[25]  E. Christophers,et al.  Erythema necroticans migrans ohne Glukagonom , 1994, Der Hautarzt.

[26]  G. Siller,et al.  GLUCAGONOMA SYNDROME WITH INCREASED LACTATE DEHYDROGENASE ISOENZYMES: OCTREOTIDE TREATMENT , 1994, The Australasian journal of dermatology.

[27]  K. Thorisdottir,et al.  Necrolytic migratory erythema: a report of three cases. , 1994, Journal of the American Academy of Dermatology.

[28]  P. Laidler,et al.  Suprabasal acantholysis—an unusual feature of necrolytic migratory erythema , 1993, Clinical and experimental dermatology.

[29]  G. Marchesini,et al.  Glucagon and amino acid disposal in normal man and in patients with cirrhosis. , 1993, The Italian journal of gastroenterology.

[30]  P. Havel,et al.  Superficial Necrolytic Dermatitis (Necrolytic Migratory Erythema) in Dogs , 1993, Veterinary pathology.

[31]  R. Hansen Dermatitis and nutritional deficiency. Diagnostic and therapeutic considerations. , 1992, Archives of dermatology.

[32]  M. Turner,et al.  Necrolytic migratory erythema without glucagonoma. , 1992, Journal of the American Academy of Dermatology.

[33]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[34]  Kasper Cs Necrolytic migratory erythema: unresolved problems in diagnosis and pathogenesis. A case report and literature review. , 1992 .

[35]  D. Roberts,et al.  Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids , 1991, The British journal of dermatology.

[36]  S. Tyring,et al.  Treatment of necrolytic migratory erythema in glucagonoma syndrome. , 1991, Journal of the American Academy of Dermatology.

[37]  J. Proietto,et al.  Reversal of a neurologic paraneoplastic syndrome with octreotide (Sandostatin) in a patient with glucagonoma. , 1991, American Journal of Medicine.

[38]  C. Kasper,et al.  Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: is hepatic impairment a clue to pathogenesis? , 1991, Journal of the American Academy of Dermatology.

[39]  E. Abell,et al.  Necrolytic migratory erythema: dyskeratotic dermatitis, a clue to early diagnosis. , 1991, Journal of the American Academy of Dermatology.

[40]  S. M. Wilkinson,et al.  Necrolytic migratory erythema: association with neuroendocrine tumour with predominant insulin secretion , 1990, The British journal of dermatology.

[41]  A. Kessinger,et al.  Glucagonoma syndrome is an underdiagnosed clinical entity. , 1990, American journal of surgery.

[42]  D. Hull,et al.  Liver Transplant for Metastatic Neuroendocrine Tumor , 1990, Journal of clinical gastroenterology.

[43]  J. Rösch,et al.  Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. , 1990, Current problems in surgery.

[44]  G. Boden Glucagonomas and insulinomas. , 1989, Gastroenterology clinics of North America.

[45]  J. Aldrete,et al.  Response of glucagonomas to surgical excision and chemotherapy. Report of two cases and review of the literature. , 1989, The American surgeon.

[46]  A. Vinik,et al.  Treatment of endocrine tumors of the pancreas. , 1989, Endocrinology and metabolism clinics of North America.

[47]  P. Keeling,et al.  Necrolytic migratory erythema with elevated plasma enteroglucagon in celiac disease. , 1989, Gastroenterology.

[48]  R. Williams,et al.  Liver transplantation for primary and secondary hepatic apudomas , 1989, The British journal of surgery.

[49]  V. Mazzaferro,et al.  Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. , 1989, Surgery, gynecology & obstetrics.

[50]  M. Papotti,et al.  A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report , 1988, Cancer.

[51]  J. Bigby Harrison's Principles of Internal Medicine , 1988 .

[52]  G. Boden Insulinoma and glucagonoma. , 1987, Seminars in oncology.

[53]  E. Lambrecht,et al.  Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. , 1987, Journal of the American Academy of Dermatology.

[54]  R. Prinz,et al.  Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. , 1986, Surgery.

[55]  L. Orci,et al.  Somatostatin Analog‐Induced Remission of Necrolytic Migratory Erythema Without Changes in Plasma Glucagon Concentration , 1986, Pancreas.

[56]  W. Grizzle,et al.  Histologic Variation in the Skin Lesions of the Glucagonoma Syndrome , 1986, The American journal of surgical pathology.

[57]  P. Sriratana,et al.  Cardiotoxicity associated with 4'-deoxydoxorubicin. , 1986 .

[58]  H. Imura,et al.  A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome , 1986, Cancer.

[59]  S. Bloom,et al.  Treatment with danazol and plasma glucagon concentration. , 1985, British medical journal.

[60]  R. P. Thompson,et al.  Glucagonoma without cutaneous manifestations. , 1985, Postgraduate medical journal.

[61]  V. Pr,et al.  Glucagonoma syndrome. A clinicopathologic, immunocytochemical, and ultrastructural study. , 1985, Journal of the American Academy of Dermatology.

[62]  Weiss Ra,et al.  DNA in medicine. Oncogenes. , 1984 .

[63]  C. Hanke,et al.  Glucagonoma syndrome: case report and literature review. , 1984, The Journal of dermatologic surgery and oncology.

[64]  K. Acott,et al.  Glucagonoma syndrome: in vitro evidence that glucagon increases epidermal arachidonic acid. , 1984, Journal of the American Academy of Dermatology.

[65]  E. Haneke [Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy]. , 1984, Zeitschrift fur Hautkrankheiten.

[66]  G. Piérard,et al.  Angioplastic necrolytic migratory erythema. Unique association of necrolytic migratory erythema, extensive angioplasia, and high molecular weight glucagon-like polypeptide. , 1982, The American Journal of dermatopathology.

[67]  K. Ohyama,et al.  Ultrastructural studies of necrolytic migratory erythema. , 1982, Archives of dermatology.

[68]  N. Walker Atypical Necrolytic Migratory Erythema in Association with a Jejunal Adenocarcinoma , 1982, Journal of the Royal Society of Medicine.

[69]  Walker Np Atypical necrolytic migratory erythema in association with a jejunal adenocarcinoma. , 1982 .

[70]  N. Samaan,et al.  Glucagonoma tumors and syndrome. , 1981, Current problems in cancer.

[71]  R. Prinz,et al.  Clinical aspects of glucagon-producing islet cell tumors. , 1981, The American journal of gastroenterology.

[72]  P. Stacpoole,et al.  The glucagonoma syndrome: clinical features, diagnosis, and treatment. , 1981, Endocrine reviews.

[73]  M. Shaffer,et al.  The glucagonoma syndrome. Report of a case. , 1980, Archives of internal medicine.

[74]  N. Vick,et al.  Neurologic involvement in glucagonoma syndrome. Response to combination chemotherapy with 5‐fluorouracil and streptozotocin , 1979, Cancer.

[75]  W. Strober,et al.  Necrolytic Migratory Erythema Without Glucagonoma: Report of Two Cases , 1979 .

[76]  J. Doyle,et al.  Hyperglucagonaemia and necrolytic migratory erythema in cirrhosis—possible pseudoglucagonoma syndrome * , 1979, The British journal of dermatology.

[77]  J. Norton,et al.  Amino acid deficiency and the skin rash associated with glucagonoma. , 1979, Annals of internal medicine.

[78]  L. G. Ortega,et al.  Necrolytic migratory erythema, presenting as candidiasis, due to a pancreatic glucagonoma , 1979, Cancer.

[79]  D. M. Stevens,et al.  The glucagonoma syndrome. , 1978, The Journal of dermatologic surgery and oncology.

[80]  R. Kahan,et al.  Necrolytic migratory erythema. Distinctive dermatosis of the glucagonoma syndrome. , 1977, Archives of dermatology.

[81]  J. Metz,et al.  [Staphylodermia superficialis circinata. The 5th obligatory cutaneous paraneoplasia]. , 1977, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[82]  O. Owen,et al.  Familial hyperglucagonemia--an autosomal dominant disorder. , 1977, The New England journal of medicine.

[83]  J. Hamer,et al.  SKIN RASH IN PATIENT RECEIVING GLUCAGON , 1976, The Lancet.

[84]  K. Hambidge,et al.  The glucagonoma syndrome (necrolytic migratory erythema) and zinc , 1976 .

[85]  H. Spiro,et al.  Glucagon secretion in acute and chronic pancreatitis. , 1975, Annals of internal medicine.

[86]  R. Sweet A dermatosis specifically associated with a tumour of pancreatic alpha cells , 1974, The British journal of dermatology.

[87]  S. Carter,et al.  Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. , 1973, Annals of internal medicine.

[88]  W. Hackeng,et al.  Glucagonoma as part of the polyglandular adenoma syndrome. , 1972, The American journal of medicine.

[89]  J. Polak,et al.  Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas , 1971, Gut.

[90]  C. Kilo,et al.  A glucagon-secreting alpha-cell carcinoma of the pancreas. , 1966, The New England journal of medicine.

[91]  R. Unger,et al.  Glucagon antibodies and an immunoassay for glucagon. , 1961, The Journal of clinical investigation.

[92]  O. Behrens,et al.  Purification and crystallization of hyperglycemic glycogenolytic factor (HGF). , 1953, Science.

[93]  S. Rothman,et al.  CUTANEOUS MANIFESTATIONS OF INTERNAL MALIGNANT TUMORS , 1942 .

[94]  H. E. Robertson,et al.  CARCINOMA OF THE ISLANDS OF THE PANCREAS: HYPERINSULINISM AND HYPOGLYCEMIA , 1927 .

[95]  J. Murlin,et al.  AQUEOUS EXTRACTS OF PANCREAS I. INFLUENCE ON THE CARBOHYDRATE METABOLISM OF DEPANCREATIZED ANIMALS , 1923 .

[96]  B. Balda,et al.  [Erythema necrolyticum migrans after rectal adenocarcinoma]. , 1998, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[97]  M. Abu el Ela,et al.  Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. , 1996, International journal of dermatology.

[98]  M. Marinkovich,et al.  Necrolytic migratory erythema without glucagonoma in patients with liver disease. , 1995, Journal of the American Academy of Dermatology.

[99]  P. Bencini,et al.  Necrolytic migratory erythema without glucagonoma in a heroin-dependent patient. , 1994, Dermatology.

[100]  C. Kasper Necrolytic migratory erythema: unresolved problems in diagnosis and pathogenesis. A case report and literature review. , 1992, Cutis.

[101]  P. Billings,et al.  A glucagonoma without necrolytic migratory erythema. , 1992, Pancreas.

[102]  R. Modigliani,et al.  Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. , 1989, Digestion.

[103]  R. Carlson,et al.  Necrolytic migratory erythema associated with odontogenic infection: an example of pseudoglucagonoma syndrome , 1988 .

[104]  Mark P. Eid Msiv Self-assessment examination of the American Academy of Dermatology. , 1987, Journal of American Academy of Dermatology.

[105]  G. Krejs Gastrointestinal endocrine tumors. , 1987, The American journal of medicine.

[106]  D. Wynick,et al.  Glucagonoma syndrome. , 1987, The American journal of medicine.

[107]  E. Kaplan,et al.  Endocrine tumors of the pancreas and their clinical syndromes. , 1986, Surgery annual.

[108]  J. Khandekar,et al.  Response of glucagonoma syndrome to lomustine. , 1986, Cancer treatment reports.

[109]  G. Kantor,et al.  Necrolytic migratory erythema-like dermatitis with malabsorption. , 1985, Cleveland Clinic quarterly.

[110]  G. Hargreaves,et al.  Necrolytic migratory erythema (glucagonoma syndrome). , 1984, Journal of the Royal Society of Medicine.

[111]  W. Fletcher,et al.  Dimethyltriazenoimidazole carboxamide therapy of islet cell carcinoma of the pancreas , 1981, Journal of surgical oncology.

[112]  D. Wilkinson Necrolytic migratory erythema with carcinoma of the pancreas. , 1973, Transactions of the St. John's Hospital Dermatological Society.

[113]  Wilkinson Ds Necrolytic migratory erythema with carcinoma of the pancreas. , 1973 .

[114]  C. de Duve,et al.  Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. , 1948, The Journal of biological chemistry.

[115]  S. A. Wilson,et al.  Disorders of motility and muscle tone with special reference to the corpus striatum , 1925 .